{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:58:27Z","timestamp":1792735107464,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013428","name":"Spieren voor Spieren","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["795655"],"award-info":[{"award-number":["795655"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004243","name":"Prinses Beatrix Spierfonds","doi-asserted-by":"publisher","award":["W.OP14-01"],"award-info":[{"award-number":["W.OP14-01"]}],"id":[{"id":"10.13039\/501100004243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004243","name":"Prinses Beatrix Spierfonds","doi-asserted-by":"publisher","award":["W.OR14-24"],"award-info":[{"award-number":["W.OR14-24"]}],"id":[{"id":"10.13039\/501100004243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004243","name":"Prinses Beatrix Spierfonds","doi-asserted-by":"publisher","award":["W.OR17-04"],"award-info":[{"award-number":["W.OR17-04"]}],"id":[{"id":"10.13039\/501100004243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Nucleic Acids"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.omtn.2021.09.010","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T21:37:37Z","timestamp":1632778657000},"page":"813-827","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Systemic delivery of a DUX4-targeting antisense oligonucleotide to treat facioscapulohumeral muscular dystrophy"],"prefix":"10.1016","volume":"26","author":[{"given":"Linde F.","family":"Bouwman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"den Hamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8950-6109","authenticated-orcid":false,"given":"Anita","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marnix","family":"Franken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrissa A.","family":"Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0319-0968","authenticated-orcid":false,"given":"Stephen J.","family":"Tapscott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Rigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silv\u00e8re M.","family":"van der Maarel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C.","family":"de Greef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2021.09.010_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2044-5040-4-12","article-title":"Facioscapulohumeral dystrophy: the path to consensus on pathophysiology","volume":"4","author":"Tawil","year":"2014","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.omtn.2021.09.010_bib2","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1126\/science.1189044","article-title":"A unifying genetic model for facioscapulohumeral muscular dystrophy","volume":"329","author":"Lemmers","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.omtn.2021.09.010_bib3","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/ng.3858","article-title":"DUX-family transcription factors regulate zygotic genome activation in placental mammals","volume":"49","author":"De Iaco","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2021.09.010_bib4","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/ng.3844","article-title":"Conserved roles of mouse DUX and human DUX4 in activating cleavage-stage genes and MERVL\/HERVL retrotransposons","volume":"49","author":"Hendrickson","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2021.09.010_bib5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.devcel.2011.11.013","article-title":"DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy","volume":"22","author":"Geng","year":"2012","journal-title":"Dev. Cell"},{"key":"10.1016\/j.omtn.2021.09.010_bib6","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0960-8966(02)00284-5","article-title":"Facioscapulohumeral muscular dystrophy (FSHD) myoblasts demonstrate increased susceptibility to oxidative stress","volume":"13","author":"Winokur","year":"2003","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.omtn.2021.09.010_bib7","doi-asserted-by":"crossref","first-page":"e04996","DOI":"10.7554\/eLife.04996","article-title":"A feedback loop between nonsense-mediated decay and the retrogene DUX4 in facioscapulohumeral muscular dystrophy","volume":"4","author":"Feng","year":"2015","journal-title":"eLife"},{"key":"10.1016\/j.omtn.2021.09.010_bib8","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1242\/jcs.205427","article-title":"The DUX4 homeodomains mediate inhibition of myogenesis and are functionally exchangeable with the Pax7 homeodomain","volume":"130","author":"Bosnakovski","year":"2017","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.omtn.2021.09.010_bib9","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1242\/jcs.180372","article-title":"DUX4 induces a transcriptome more characteristic of a less-differentiated cell state and inhibits myogenesis","volume":"129","author":"Knopp","year":"2016","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.omtn.2021.09.010_bib10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/jmedgenet-2011-100454","article-title":"Facioscapulohumeral muscular dystrophy: new insights from compound heterozygotes and implication for prenatal genetic counselling","volume":"49","author":"Scionti","year":"2012","journal-title":"J.\u00a0Med. Genet."},{"key":"10.1016\/j.omtn.2021.09.010_bib11","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ng.2454","article-title":"Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2","volume":"44","author":"Lemmers","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2021.09.010_bib12","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ajhg.2016.03.013","article-title":"Mutations in DNMT3B Modify Epigenetic Repression of the D4Z4 Repeat and the Penetrance of Facioscapulohumeral Dystrophy","volume":"98","author":"van den Boogaard","year":"2016","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtn.2021.09.010_bib13","doi-asserted-by":"crossref","first-page":"e2441","DOI":"10.1212\/WNL.0000000000009617","article-title":"Homozygous nonsense variant in LRIF1 associated with facioscapulohumeral muscular dystrophy","volume":"94","author":"Hamanaka","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2021.09.010_bib14","doi-asserted-by":"crossref","first-page":"e26820","DOI":"10.1371\/journal.pone.0026820","article-title":"The FSHD atrophic myotube phenotype is caused by DUX4 expression","volume":"6","author":"Vanderplanck","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtn.2021.09.010_bib15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3390\/genes8030093","article-title":"Antisense Oligonucleotides Used to Target the DUX4 mRNA as Therapeutic Approaches in FaciosScapuloHumeral Muscular Dystrophy (FSHD)","volume":"8","author":"Ansseau","year":"2017","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.omtn.2021.09.010_bib16","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/mt.2016.111","article-title":"Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics","volume":"24","author":"Chen","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2021.09.010_bib17","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/hmg\/ddw015","article-title":"Antisense targeting of 3\u2032 end elements involved in DUX4 mRNA processing is an efficient therapeutic strategy for facioscapulohumeral dystrophy: a new gene-silencing approach","volume":"25","author":"Marsollier","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2021.09.010_bib18","doi-asserted-by":"crossref","first-page":"16509","DOI":"10.1073\/pnas.1909649117","article-title":"Inhibition of DUX4 expression with antisense LNA gapmers as a therapy for facioscapulohumeral muscular dystrophy","volume":"117","author":"Lim","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2021.09.010_bib19","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.ymthe.2020.10.010","article-title":"DUX4 Transcript Knockdown with Antisense 2\u2032-O-Methoxyethyl Gapmers for the Treatment of Facioscapulohumeral Muscular Dystrophy","volume":"29","author":"Lim","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2021.09.010_bib20","doi-asserted-by":"crossref","first-page":"e0192657","DOI":"10.1371\/journal.pone.0192657","article-title":"A cre-inducible DUX4 transgenic mouse model for investigating facioscapulohumeral muscular dystrophy","volume":"13","author":"Jones","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtn.2021.09.010_bib21","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/hmg\/ddab136","article-title":"Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model","volume":"30","author":"Lu-Nguyen","year":"2021","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2021.09.010_bib22","doi-asserted-by":"crossref","first-page":"6029","DOI":"10.1093\/nar\/gkz354","article-title":"Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle","volume":"47","author":"Prakash","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2021.09.010_bib23","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/ng.3846","article-title":"Conservation and innovation in the DUX4-family gene network","volume":"49","author":"Whiddon","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.omtn.2021.09.010_bib24","doi-asserted-by":"crossref","first-page":"e1003415","DOI":"10.1371\/journal.pgen.1003415","article-title":"Intrinsic epigenetic regulation of the D4Z4 macrosatellite repeat in a transgenic mouse model for FSHD","volume":"9","author":"Krom","year":"2013","journal-title":"PLoS Genet."},{"key":"10.1016\/j.omtn.2021.09.010_bib25","doi-asserted-by":"crossref","first-page":"e0220665","DOI":"10.1371\/journal.pone.0220665","article-title":"Cross-sectional study into age-related pathology of mouse models for limb girdle muscular dystrophy types 2D and 2F","volume":"14","author":"Verhaart","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtn.2021.09.010_bib26","doi-asserted-by":"crossref","first-page":"8110","DOI":"10.1096\/fj.201802488R","article-title":"Natural disease history of the D2-mdx mouse model for Duchenne muscular dystrophy","volume":"33","author":"van Putten","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.omtn.2021.09.010_bib27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13395-020-00227-4","article-title":"Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity","volume":"10","author":"Jones","year":"2020","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.omtn.2021.09.010_bib28","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/hmg\/ddaa031","article-title":"Longitudinal measures of RNA expression and disease activity in FSHD muscle biopsies","volume":"29","author":"Wong","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2021.09.010_bib29","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2021.09.010_bib30","doi-asserted-by":"crossref","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2021.09.010_bib31","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.omtn.2021.09.010_bib32","doi-asserted-by":"crossref","first-page":"30377","DOI":"10.1038\/srep30377","article-title":"Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides","volume":"6","author":"Kasuya","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.omtn.2021.09.010_bib33","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1053\/j.ajkd.2013.02.359","article-title":"Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9","volume":"62","author":"van Poelgeest","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.omtn.2021.09.010_bib34","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/nat.2013.0422","article-title":"Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys","volume":"23","author":"Burel","year":"2013","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.omtn.2021.09.010_bib35","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.omtn.2017.05.007","article-title":"Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice","volume":"7","author":"Jauvin","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2021.09.010_bib36","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1124\/jpet.115.226969","article-title":"Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1","volume":"355","author":"Pandey","year":"2015","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.omtn.2021.09.010_bib37","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.celrep.2014.02.008","article-title":"Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy","volume":"7","author":"Lieberman","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2021.09.010_bib38","doi-asserted-by":"crossref","first-page":"e7482","DOI":"10.1371\/journal.pone.0007482","article-title":"DUX4c is up-regulated in FSHD. It induces the MYF5 protein and human myoblast proliferation","volume":"4","author":"Ansseau","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtn.2021.09.010_bib39","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13395-017-0148-4","article-title":"Overexpression of the double homeodomain protein DUX4c interferes with myofibrillogenesis and induces clustering of myonuclei","volume":"8","author":"Vanderplanck","year":"2018","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.omtn.2021.09.010_bib40","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1212\/01.wnl.0000254991.21818.f3","article-title":"Genotype-phenotype study in an FSHD family with a proximal deletion encompassing p13E-11 and D4Z4","volume":"68","author":"Deak","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.omtn.2021.09.010_bib41","article-title":"Chromosome 10q-linked FSHD identifies DUX4 as principal disease gene","author":"Lemmers","year":"2021","journal-title":"J.\u00a0Med. Genet."},{"key":"10.1016\/j.omtn.2021.09.010_bib42","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.scr.2012.08.003","article-title":"DUXO, a novel double homeobox transcription factor, is a regulator of the gastrula organizer in human embryonic stem cells","volume":"9","author":"Sharon","year":"2012","journal-title":"Stem Cell Res. (Amst.)"},{"key":"10.1016\/j.omtn.2021.09.010_bib43","doi-asserted-by":"crossref","first-page":"e1001181","DOI":"10.1371\/journal.pgen.1001181","article-title":"Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene","volume":"6","author":"Snider","year":"2010","journal-title":"PLoS Genet."},{"key":"10.1016\/j.omtn.2021.09.010_bib44","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1582-4934.2012.01647.x","article-title":"DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy?","volume":"17","author":"Tassin","year":"2013","journal-title":"J.\u00a0Cell. Mol. Med."},{"key":"10.1016\/j.omtn.2021.09.010_bib45","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1093\/hmg\/ddv315","article-title":"Endogenous DUX4 expression in FSHD myotubes is sufficient to cause cell death and disrupts RNA splicing and cell migration pathways","volume":"24","author":"Rickard","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtn.2021.09.010_bib46","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1261\/rna.070177.118","article-title":"RNAscope in\u00a0situ hybridization-based method for detecting DUX4 RNA expression in\u00a0vitro","volume":"25","author":"Amini Chermahini","year":"2019","journal-title":"RNA"},{"key":"10.1016\/j.omtn.2021.09.010_bib47","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ebiom.2019.06.036","article-title":"Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases","volume":"45","author":"Tsoumpra","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.omtn.2021.09.010_bib48","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/nar\/gkl1071","article-title":"Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals","volume":"35","author":"Swayze","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtn.2021.09.010_bib49","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Molecular Therapy - Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253121002390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253121002390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T01:33:31Z","timestamp":1761874411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253121002390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":49,"alternative-id":["S2162253121002390"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2021.09.010","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic delivery of a DUX4-targeting antisense oligonucleotide to treat facioscapulohumeral muscular dystrophy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2021.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s).","name":"copyright","label":"Copyright"}]}}